List of Cell Therapies Companies in Denmark - 6

Aarhus University is a higher education institution that focuses on research and academic programs.

From our headquarters in Copenhagen, we develop and manufacture vaccines, diagnostics, and therapeutic solutions for the world. We are proud to contribute to disease control in more than 50 countries through our collaboration with WHO and UNICEF. We have more than 600 colleagues, and we pride ourselves on being a diverse workforce with passports from 39 nationalities. Being part of AJ Vaccines means joining a common mission towards a healthier and safer world. Whether you're an experienced professional or an emerging talent, you'll find a platform here to contribute, innovate, and create meaningful change.

At ALK, we go to work every day to make a difference for the many people with allergies around the world. It is our ambition to make life with allergy surprisingly simple for as many people as possible, and we build upon our strong heritage as a pioneer in allergy immunotherapy, when we continue to innovate, develop and market new products and solutions to help improve the health of people with allergies. Every day, our employees contribute to our aspiration of becoming the world leader in allergy by coming to work to do their best in the pursuit of providing new and better allergy treatments and solutions. We work in a high-energy, international setting where it is imperative that our people thrive and develop. Creativity, influence and opportunities are key elements in developing our people. ALK is a global company with production sites in Denmark, France, Spain and the United States. ALK was founded in Copenhagen in 1923 and today we employ around 2,900 people around the world. Our global headquarters is located in beautiful surroundings in Hørsholm, north of Copenhagen. Read more about ALK at www.alk.net

BOOST Pharma is based on years of collaborative research from Karolinska Institute in Stockholm with the focus on novel cell therapy treatments for Osteogenesis Imperfecta. The research teams of associate professor Cecilia Götherström and professor Magnus Westgren have shown that that treatment with BOOST Cells greatly enhanced the quality of life for patients suffering from this otherwise extremely debilitating disease.

Cytovac has the key to immunotherapy Cytovac is a growing Danish biotech company, focusing on development of a cancer treatment that uses the body’s own immune system. Promising results gained by the dedicated research team over a number of years, have brought about the development of the ALECSAT therapy. ALECSAT is a therapy based on injection of activated cells from the immune system. These cells will attack the cancer cells and activate the immune system in the patients. As Cytovac solely apply the patient’s own cells, this therapy is gentle and without the serious side effects normally associated with cancer treatment. Cytovac has been granted Orphan Drug Designation by the European (EMA) as well as the American (FDA) medicines agencies in support to the company’s brain-cancer project. Cytovac has generated convincing data with the ALECSAT treatments in three clinical phase I trials targeted at treatment of prostate cancer, pancreatic cancer and brain cancer. So far more than 100 cancer patients have been treated, with more than 250 doses of ALECSAT. So Cytovac has a platform that may prove to be an efficacious treatment for several types of cancer. Cytovac has since 2015 concentrated all clinical efforts on brain cancer, and here the company is currently conducting clinical phase II trials. Cytovac is dedicated to treatment of cancer by using our key to immunotherapy.

Fida Biosystems (Fidabio) offers a new proprietary technology developed for quantification and characterization of proteins and nanoparticles from 0.5 to 1,000 nm Dh, incl. antibodies, liposomes, exosomes, membrane embedded proteins et al. Based on accurate, in-solution, absolute measurements of hydrodynamic radius, the technology provides precise information about Kd, concentration, size, stoichiometry, conformational changes, oligomeric state, immunogenicity, multiple bindings etc. It is characterised by being fast (minutes), requiring very small sample amounts (ul-nl), and being exceptionally tolerant to the sample matrix, incl. plasma, serum, cell lysate, fermentation media etc. Contrary to most other procedures, the methodology is based on binding in homogenous solution; complications related to non-specific surface adsorption and challenging assay development are therefore avoided. I.e. the unique features of the FIDA technology enable characterisation and quantification in native (biorelevant) environments and in-built assay quality control and automation.